-
Topical Pain Relief Market to Reach US$17.3 Bn by 2033, Growing at 5.2% CAGR: Persistence Market Research
03 Feb 2026 07:03 GMT
… )
By Distribution Channel
Pharmacy & Drug Stores
Retail Stores
Online Stores … , Advacare Pharma, Teva Pharmaceutical Industries, Bayer Healthcare, and GlaxoSmithKline leading the charge …
-
Bioengineered Protein Drugs Market Set to Reach $593.3 Billion by 2029
24 Nov 2025 10:30 GMT
… Bioengineered Protein Drugs include:
• Abbvie Inc.
• Amgen Inc.
• Astrazeneca PLC
• Bayer HealthCare Pharmaceuticals … , Peptide Antibiotics, Therapeutic Enzymes, Other Drug Type
2) By Technology: Bioreactors …
-
FDA Approves New Drug for Treating Most Common Type of Lung Cancer, Based on Broad Institute Research
25 Nov 2025 08:26 GMT
… Harvard and MIT, and Bayer Healthcare Pharmaceuticals, a global healthcare … molecule that comprises the drug were unstable, Greulich said … also approved zongertinib, another drug for NSCLC patients. … developing zongertinib, both drugs add value by providing …
-
FDA approves first cancer drug based on Broad Institute science
20 Nov 2025 23:26 GMT
… approved the first cancer drug based on discoveries from … scientists. The drug, sevabertinib, was developed by Bayer Healthcare Pharmaceuticals in close … benefit from this new drug. Many of these patients … ;t respond to existing drugs had a mutation in their …
-
RET Fusion Targeted Therapies Market Set for Robust Growth by 2034 Amid Precision Oncology Shift | DelveInsight
27 Jan 2026 00:50 GMT
… RET Fusion Targeted Therapies Drugs
Competitive Intelligence Analysis: SWOT … medullary thyroid cancer companies, including Bayer HealthCare, TYK Medicines, Inc., Applied … among others.
Antibody Drug Conjugates Market
Antibody Drug Conjugates Market Size, …
-
Finerenone plus SGLT2 inhibitor reduces albuminuria more than either drug alone
06 Jun 2025 18:02 GMT
… and empagliflozin than with either drug alone, according to study … “[The combination] is safe, and drug discontinuation due to hypotension, acute … support from Akebia Therapeutics, Alnylam, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim, Chinook, …
-
U.S. Orphan Designated Drugs Market Research Report 2025: $190 Billion Opportunities, Drugs Sales, Price, Dosage & Clinical Trials Insights to 2030 - ResearchAndMarkets.com
19 May 2025 18:48 GMT
… associated with orphan drug development can be significant.
More drugs have over … years acquired orphan drug status. To date, hundreds of drugs in development …
10.8 AstraZeneca
10.9 Bayer HealthCare
10.10 BioMarin Pharmaceutical
10 …
-
Real-World Analysis of Multidisciplinary Roles in the Management of Hepatocellular Carcinoma: The Mayo Clinic Experience
21 Jan 2026 22:55 GMT
… , keyword searches included the drug names: “Sorafenib” (Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA … ., Alameda, CA, USA), and “Regorafenib” (Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ, USA …
-
Liver Fluke Treatment Market Growth Drivers, Industry Trends And Forecasts 2025-2034 | Global Liver Fluke Treatment Market Grows At 4.8% CAGR Amid Rising Anthelmintic Drug Demand
14 Apr 2025 12:59 GMT
… pharmaceutical formulations, including controlled drug release mechanisms and improved bioavailability … to commonly used anthelmintic drugs
3.3 Growth potential … 10 Company Profiles AdvaCare Pharma Bayer Healthcare GlaxoSmithKline Lupin Pharma Merck …
-
The Search for a Safer Anticoagulant
20 Jan 2026 12:10 GMT
… 10 times more for this drug than for apixaban?”
Based on … OCEANIC trials were funded by Bayer HealthCare. The LIBREXIA studies were funded … an advisor or consultant for Bayer HealthCare, Bristol-Myers Squibb, Janssen Pharmaceuticals …
About
© 1995-2026